SLC5A2 and type 2 diabetes mellitus: Sodium/Glucose cotransporter-2 inhibitors (SGLT-2) are oral antihyperglycemics approved for the management of type 2 diabetes mellitus (DM) (Nespoux and Vallon 2020).